Short Summary
The case was received by the Calcutta High Court from the Intellectual Property Appellate Board (IPAB) following the enactment of the Tribunals Reform Act, 2021. The court directed its Commercial Appellate Division to issue notices and file a report before setting the matter for further hearing.
Detailed Summary
When a government tribunal that has been adjudicating your patent dispute for years is suddenly dissolved overnight, where does your case go? For Tata Chemicals Limited, this was not a hypothetical question — it became a stark reality when India's Intellectual Property Appellate Board (IPAB) was abolished under the Tribunals Reform Act, 2021. The case serves as a powerful reminder that the legal infrastructure underpinning intellectual property disputes can shift beneath a company's feet, and founders must understand how procedural transitions can impact even the most established players.
Tata Chemicals Limited, one of India's most recognized industrial conglomerates, found itself in a patent dispute with the Assistant Controller of Patents. The matter had been pending before the Intellectual Property Appellate Board, the specialized body that historically handled appeals related to patent decisions made by the Patent Office. However, the legal landscape changed dramatically with the enactment of the Tribunals Reform Act, 2021, which dissolved several tribunals including the IPAB. As a result, all pending appeals were transferred to the respective High Courts. On 17 January 2023, the matter landed before the Calcutta High Court, which had to determine how to handle this inherited caseload.
The core legal friction in this case was not about the substantive patent issues themselves, but rather about procedural jurisdiction and transition. Tata Chemicals, as the petitioner, was seeking appellate review of a decision by the Assistant Controller of Patents. The respondent was the patent authority itself. The real question before the Calcutta High Court was procedural: how should the court absorb and process appeals that were originally filed before a now-defunct tribunal? The court had to establish a mechanism for receiving these transferred matters and ensuring that litigants like Tata Chemicals were not left in legal limbo.
On 17 January 2023, the Calcutta High Court addressed the procedural question by directing its Commercial Appellate Division to take cognizance of the matter. The court ordered that notices be issued to the relevant parties and that a report be filed before the matter could be set down for further hearing. The case was kept pending, awaiting the completion of these procedural steps. No substantive ruling on the underlying patent dispute was issued at this stage — the court's focus was squarely on ensuring a smooth transition of jurisdiction from the abolished IPAB to the High Court framework.
For founders, startup leaders, and IP professionals, this case underscores a critical lesson: the procedural architecture of intellectual property litigation is not static. The abolition of the IPAB and the transfer of its caseload to High Courts means that patent appeals now face different timelines, procedural rules, and forums than they did before 2021. Companies with pending or potential patent disputes must stay informed about which court has jurisdiction over their matters and adapt their legal strategies accordingly. More broadly, this case highlights the importance of building flexibility into your IP litigation strategy — because the forum, not just the facts, can determine the trajectory of your case.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Calcutta High Court. Understanding the court's reasoning in Tata Chemicals Limited vs The Assistant Controller Of Patents And Designs is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Unilever Plc.vsAman Chauhan
In this interim application concerning trademark and copyright infringement, Unilever Plc. sought a short adjournment to continue identifying the true parties involved in the counterfeiting operation. The court noted that amendments had been made to implead the party found at the premises during the execution of an earlier ad-interim order. Given that Unilever was still actively tracing the ultimate owner of the infringing premises, the High Court granted the request for adjournment until May 4, 2022, ensuring the existing protective orders remained in force.
Hero Investcorp Private Limited & AnrvsM.M. Oil Traders
The Delhi High Court granted several interim reliefs in favor of Hero Investcorp Private Limited, which is suing M.M. Oil Traders for infringement. The court allowed the plaintiffs to file additional documents and exempted them from advance service and pre-institution mediation due to the urgent nature of the case. Crucially, the court appointed a Local Commissioner with broad powers to confiscate infringing products and inspect the defendant's accounts, signaling strong judicial support for the plaintiff's claims regarding trademark, design, and copyright infringement.
Ohr Laboratory CorporationvsGasion Airtech Private Limited & Ors
The Delhi High Court granted an ad interim injunction in favor of Ohr Laboratory Corporation against Gasion Airtech Private Limited & Ors. The court found that the Plaintiff had made out a prima facie case, irreparable harm would result without intervention, and the balance of convenience favored the Plaintiff. Defendants are now restrained from using the 'OHR' mark or similar names/model numbers, as well as from reproducing copyrighted brochure elements.
Titan Company LimitedvsM/S Bihani Jewellers & Anr.
Titan Company Limited filed a suit against M/S Bihani Jewellers & Anr., alleging infringement of its registered trademarks, copyrighted images, and registered designs associated with the 'Tanishq' brand. The Plaintiff claimed that the Defendants were using these proprietary assets on their website and social media to sell jewellery products. After considering the submissions, including an undertaking from the Defendants, the court decreed the suit.
Novartis AG & Anr.vsTorrent Pharmaceuticals Limited
Novartis AG sued Torrent Pharmaceuticals for infringement of Indian Patent No. 275655 covering the anti-cancer drug Dabrafenib. Torrent accepted summons and voluntarily undertook not to manufacture, launch, import, export, or deal in any Dabrafenib-containing API or formulation during the patent's validity. The Delhi High Court accepted the undertaking as part of the decree, effectively granting Novartis the relief of a permanent injunction without contest, while preserving Torrent's rights under Section 107A of the Patents Act to use the compound for research purposes.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.